Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
therapeutic cytotoxic T lymphocytes-Fred Hutchinson Cancer Center-metastatic melanoma
- Development stage
- Unknown
- Lead developer
- Fred Hutchinson Cancer Center
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Cell Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
therapeutic cytotoxic T lymphocytes-Fred Hutchinson Cancer Center-metastatic melanoma refers to an investigational adoptive cell therapy regimen developed by the Fred Hutchinson Cancer Center for the treatment of metastatic melanoma. This therapeutic approach involves the infusion of autologous cytotoxic T lymphocytes (CTLs) that have been expanded ex vivo and primed with interleukin-21 (IL-21) to enhance their anti-tumor potency and long-term persistence. The regimen is administered in combination with the CTLA-4 checkpoint inhibitor ipilimumab to further stimulate the immune response, along with lymphodepleting cyclophosphamide and supportive low-dose aldesleukin (IL-2). By combining tumor-specific T-cell transfer with checkpoint blockade, the therapy aims to overcome the immunosuppressive tumor microenvironment and achieve durable clinical responses in patients with advanced melanoma.
- Other names
- Laboratory-Treated T Cells and IpilimumabIL-21-primed autologous CTLs + ipilimumabtherapeutic cytotoxic T lymphocytes
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)TAA-pMHC-I (Tumor-associated antigen peptide–Major Histocompatibility Complex class I)
Beyond the preview
Go deeper on therapeutic cytotoxic T lymphocytes-Fred Hutchinson Cancer Center-metastatic melanoma.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on therapeutic cytotoxic T lymphocytes-Fred Hutchinson Cancer Center-metastatic melanoma.